Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction

Circulation

Volumn 123, Issue 4, 2011, Pages 400-408

  Fraccarollo, Daniela ^a,b   Berger, Stefan ^c   Galuppo, Paolo ^a,b   Kneitz, Susanne ^b   Hein, Lutz ^d   Schütz, Günther ^c   Frantz, Stefan ^b   Ertl, Georg ^b   Bauersachs, Johann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

acute myocardial infarction; aldosterone; heart failure; mineralocorticoid receptor; remodeling

Indexed keywords

ALDOSTERONE; COLLAGEN; CORTICOSTERONE; CRE RECOMBINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; MYOSIN LIGHT CHAIN 2; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ALDOSTERONE BLOOD LEVEL; ALLELE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARDIOMEGALY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORTICOSTERONE BLOOD LEVEL; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE SILENCING; HEALING; HEART CATHETERIZATION; HEART CONDUCTION; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE REMODELING; IRRADIATION; LUNG EDEMA; MITOCHONDRION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; UPREGULATION;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CELLS, CULTURED; CORONARY VESSELS; FEMALE; GENE DELETION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NADPH OXIDASE; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PULMONARY EDEMA; RECEPTORS, MINERALOCORTICOID; SUPEROXIDES; UP-REGULATION; VENTRICULAR REMODELING;

EID: 79751529118     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.983023     Document Type: Article

References (47)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. (Pubitemid 36384098)
3. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, Van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-431. (Pubitemid 41040281)
4. Adamopoulos C, Ahmed A, Fay R, Angioi M, Filippatos G, Vincent J, Pitt B, Zannad F. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009;11:1099-1105.
5. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565. (Pubitemid 36628936)
6. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:2471-2479.
7. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003; 42:1666-1673. (Pubitemid 37378451)
8. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, Van Rooijen N, Ertl G, Bauersachs J. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008;51:905-914. (Pubitemid 351654703)
9. Pitt B, Pitt GS. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation. 2007;115: 2976-2982. (Pubitemid 46912101)
10. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM, Benitah JP. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation. 2004;110:776-783. (Pubitemid 39096003)
11. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. (Pubitemid 40847778)
12. Schafer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res. 2003;58:655-662. (Pubitemid 36694451)
13. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I, Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension. 2007;50:919-925. (Pubitemid 350287535)
14. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13:189-197.
15. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101: 2981-2988. (Pubitemid 30415891)
16. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, Chepkova AN, Welzl H, Haas HL, Lipp HP, Schutz G. Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA. 2006;103:195-200. (Pubitemid 43076127)
17. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of galphaq/galpha11 in cardiomyocytes. Nat Med. 2001;7:1236-1240. (Pubitemid 33063779)
18. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, Galuppo P, Strotmann J, Ertl G, Bauersachs J. Peroxisome proliferator activatedreceptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol. 2004;141:9-14. (Pubitemid 38241158)
19. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248. (Pubitemid 46142995)
20. Matsushima S, Ide T, Yamato M, Matsusaka H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara T, Oikawa S, Kinugawa S, Tsutsui H. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 2006;113:1779-1786. (Pubitemid 43958471)
21. Vanhoutte D, Schellings MW, Gotte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortes V, Rigotti A, Stepp MA, Van De Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007;115:475-482. (Pubitemid 46184199)
22. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol. 2010;48: 504-511.
23. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res. 2009;81:474-481.
24. Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R. Aldosterone abrogates nuclear factor kappab-mediated tumor necrosis factor alpha production in human neutrophils via the mineralocorticoid receptor. Hypertension. 2010;55:370-379.
25. Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, Sivasubramanian N, Olson EN, Entman ML, Mann DL. Nuclear factorkappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation. 2003;108:3075-3078. (Pubitemid 38031794)
26. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res. 2008;31:363-375. (Pubitemid 351461117)
27. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
28. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol. 1997;158:3483-3491. (Pubitemid 127484070)
29. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669-671. (Pubitemid 20356243)
30. Pan ZZ, Parkyn L, Ray A, Ray P. Inducible lung-specific expression of RANTES: preferential recruitment of neutrophils. Am J Physiol. 2000; 279:L658-L666.
31. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem. 2001;276:38911-38920.
32. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone induces angiotensinconverting- enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139. (Pubitemid 32655827)
33. Di Zhang A, Cat AN, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008; 52:1060-1067.
34. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med. 2008;86:673-678.
35. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, Bauersachs J. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of thioredoxin 2. Hypertension. 2009;54:338-344.
36. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005; 46:555-561. (Pubitemid 41376837)
37. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253-1264.
38. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286-290.
39. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2:608-615.
40. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761. (Pubitemid 46648612)
41. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation. 2005;111:1652-1659. (Pubitemid 40525165)
42. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S, Friedrich B, Grahammer F, Belaiba RS, Gorlach A, Wulff P, Daut J, Dalton ND, Ross J Jr, Flogel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med. 2006;84:396-404. (Pubitemid 43673614)
43. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, Jones WK, Dorn GW. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest. 2007;117: 2825-2833. (Pubitemid 47529613)
44. Regula KM, Baetz D, Kirshenbaum LA. Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes. Circulation. 2004;110:3795-3802. (Pubitemid 40023978)
45. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med. 1997;3:158-164. (Pubitemid 27064699)
46. McSweeney SJ, Hadoke PW, Kozak AM, Small GR, Khaled H, Walker BR, Gray GA. Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI. Cardiovasc Res. 2010;88:159-167.
47. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-Rasa and MAPK1/2 signaling. Am J Physiol. 2003;284:H176-H184. (Pubitemid 36076284)